Diagnosis and management of nonvariceal upper gastrointestinal bleeding.
Nonvariceal upper gastrointestinal bleeding (UGIB) is a major cause of morbidity and mortality worldwide. Despite the improvements in the management of this condition in western countries, mortality rates have remained at 5-10% over the past decade. This article presents the main recommendations for the management of UGIB. Pre-endoscopic management (including use of scoring scales, nasogastric tube placement and blood pressure stabilization) is crucial for triage and optimal resuscitation of patients, and should include a multidisciplinary approach at an early stage. Unless the patient has specific comorbidities, transfusion should only be considered if their hemoglobin level is ≤70 g/l. Endoscopic therapy, the cornerstone of therapeutic management of high-risk lesions, should not be delayed for more than 24 h following admission. Several endoscopic techniques, mostly using clips or thermal methods, are available and new approaches are emerging. When endoscopy fails, surgery or arterial embolization should be considered. Although the efficacy of prokinetics and high-dose intravenous PPI prior to endoscopy is controversial, the use of an intravenous PPI following endoscopy is strongly recommended. Antiplatelet therapy should be suspended and resumed in 3-5 days. Finally, all patients should be tested for Helicobacter pylori by serology in the acute setting.
National Institute for Health and Medical Research (INSERM), CIC-P 803, Department of Gastroenterology, Centre Hospitalier Universitaire de Dijon, 14 rue Gaffarel, BP77908, 21079 Dijon, France. marc.bardou@ u-bourgogne.fr
Marc
M
Bardou
Dalila
D
Benhaberou-Brun
Isabelle
I
Le Ray
Alan N
AN
Barkun
D019468:Disease Management; D006471:Gastrointestinal Hemorrhage / Q000175:diagnosis / Q000209:etiology / Q000628:therapy; D016481:Helicobacter Infections / Q000150:complications / Q000175:diagnosis / Q000628:therapy; D016480:Helicobacter pylori / Q000302:isolation & purification*; D016558:Hemostasis, Endoscopic / Q000379:methods*; D006801:Humans; D011379:Prognosis; D054328:Proton Pump Inhibitors / Q000627:therapeutic use*; D012720:Severity of Illness Index
D054328:Proton Pump Inhibitors